🧠 This Week in Immunology: FDA Approvals, Gene Therapy Breakthroughs & Pipeline Shifts
Catch the latest headlines shaping immunology—from groundbreaking trials to strategic exits and first-in-class therapies.
🔍 What’s Inside This Week’s Immunology Briefing:
💉 TREMFYA® SC shows significant clinical remission in ulcerative colitis
📈 Abivax completes enrollment of over 1,200 patients in Phase 3 UC trials
🧪 Xencor’s XmAb942 advances with a half-life exceeding 71 days
🔁 FDA approves SELARSDI™, a biosimilar to Stelara®
🧬 Cullinan initiates first CD19 T-cell engager trial in Sjögren’s disease
🔄 AstraZeneca exits neuroscience to double down on immunology and obesity
🧫 Gene therapy ZEVASKYN™ approved for RDEB wound healing, with greater than 80% efficacy
👃 neffy® nasal epinephrine expands pediatric reach nationwide
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on immunology, IBD, autoimmune disease, and more
#Immunology #UlcerativeColitis #GeneTherapy #IBD #AutoimmuneDisease #ClinicalTrials #Biosimilars #TREMFYA #neffy #RDEB #LucidQuest #HealthcareInnovation #FDAapproval #MedicalNews